• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxamides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids and derivatives Piperidinecarboxamides

Introduction to N-(Pyridin-4-yl)piperidine-4-carboxamide (CAS No. 110105-35-6)

N-(Pyridin-4-yl)piperidine-4-carboxamide (CAS No. 110105-35-6) is a significant compound in the realm of pharmaceutical chemistry, exhibiting a unique structural framework that has garnered considerable attention from researchers worldwide. This compound, characterized by its pyridine and piperidine moieties, serves as a versatile scaffold for the development of novel therapeutic agents.

The molecular structure of N-(Pyridin-4-yl)piperidine-4-carboxamide consists of a pyridine ring substituted at the 4-position with an amide-linked piperidine ring. This particular arrangement imparts favorable physicochemical properties, including solubility and metabolic stability, making it an attractive candidate for further medicinal chemistry exploration. The presence of both nitrogen-rich heterocycles enhances its potential as a pharmacophore, capable of interacting with various biological targets.

In recent years, there has been a surge in research focused on developing small molecule inhibitors targeting protein-protein interactions (PPIs), which play crucial roles in numerous disease pathways. N-(Pyridin-4-yl)piperidine-4-carboxamide has emerged as a promising lead compound in this area due to its ability to modulate PPIs through its dual-heterocyclic system. Studies have demonstrated its potential in inhibiting key enzymes involved in cancer progression, inflammation, and neurodegenerative disorders.

One of the most compelling aspects of N-(Pyridin-4-yl)piperidine-4-carboxamide is its versatility in drug design. Researchers have leveraged its scaffold to develop derivatives with enhanced binding affinity and selectivity. For instance, modifications at the amide linkage have been explored to optimize pharmacokinetic profiles, while alterations at the pyridine ring have been employed to fine-tune target interactions.

The synthesis of N-(Pyridin-4-yl)piperidine-4-carboxamide involves multi-step organic transformations, typically starting from commercially available pyridine derivatives and piperidine precursors. Advanced synthetic methodologies, such as transition metal-catalyzed cross-coupling reactions and palladium-mediated transformations, have been employed to construct the desired core structure efficiently. These synthetic strategies not only ensure high yields but also facilitate the introduction of diverse functional groups for further derivatization.

The pharmacological evaluation of N-(Pyridin-4-yl)piperidine-4-carboxamide has revealed intriguing biological activities. Preclinical studies have highlighted its potential in inhibiting kinases and other enzymes implicated in cancer signaling pathways. Additionally, its ability to modulate neurotransmitter receptors has sparked interest in its potential therapeutic applications for central nervous system disorders.

In conclusion, N-(Pyridin-4-yl)piperidine-4-carboxamide (CAS No. 110105-35-6) represents a significant advancement in pharmaceutical chemistry. Its unique structural features and demonstrated biological activities make it a valuable tool for drug discovery and development. As research continues to uncover new therapeutic targets and mechanisms, this compound is poised to play a pivotal role in the next generation of innovative treatments.

• 146986-50-7(Y-27632)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)